Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

Senile systemic amyloidosis is primarily related to cardiac involvement including congestive heart failure, cardiomyopathy with diastolic dysfunction, angina, arrhythmias, pericardial effusion ...

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

March 25, 2025 – The FDA has approved a new treatment for adults with a life-threatening heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a rare but serious ...

CHICAGO — RNA therapeutics improved survival, 6-minute walk distance and quality of life for patients with transthyretin amyloid cardiomyopathy, according to study results presented at the ...

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval.

Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis (ATTR-CM), allowing it to compete head-to-head with rival therapies ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Tafamidis and tafamidis meglumine may help treat transthyretin amyloid cardiomyopathy (ATTR-CM). Medicare Part D prescription drug plans may cover the cost of these medications. Transthyretin ...